Merck and Moderna have reported positive Phase 3 data. The vaccine, when tested with an existing immunotherapy, significantly slowed the return of melanoma and its spread to other parts of the body.

Manufacturing readiness is not a contingency plan. It is standing capacity that keeps running when nothing is happening, and it is now a competitive advantage.

A practical framework for choosing the right CDMO for advanced therapy development, including a weighted scorecard, an evaluation sequencing model, and the decision pitfalls to avoid.

New center integrates synthetic DNA, mRNA, targeted delivery, and GMP drug product capabilities to help innovators advance genetic medicines from early development through commercial supply

Rebrand unifies U.S. and European operations under a single Artis brand, connecting synthetic DNA starting material to downstream development and manufacturing services

Landmark Bio, an Artis BioSolutions company dedicated to accelerating the translation of next-generation advanced therapies from discovery to clinical and commercial production, today announced that it has secured an Advanced Research Projects Agency for Health (ARPA-H) award totaling up to $18.3 million to build an efficient, robust, and scalable continuous manufacturing platform for extracellular vesicles (EVs).